Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Dendreon: Watch the Cost Curve Being Bent | Main | Bernard Munos Rides Again »

August 4, 2011

Does Anyone Want Axanum?

Email This Entry

Posted by Derek

While we're talking about the cost of drugs, is AstraZeneca really going to be able to sell anyone any Axanum? That's a combination pill of Nexium (esomeprazole) and low-dose aspirin. The FDA didn't go for it last year, but the InVivoBlog details the company's attempts to get it on the market across Europe. Seeing as how AZ's drug is staggering off patent protection in Europe, and seeing as how low-dose aspirin is cheaper than the better grades of dirt, I just don't see how they sell any of this stuff. But desperate times, desperate measure and all that, I guess. . .

Comments (21) + TrackBacks (0) | Category: Drug Prices


COMMENTS

1. PharmaHeretic on August 4, 2011 1:08 PM writes...

Desperate times call for desperate measures.

Permalink to Comment

2. PharmaHeretic on August 4, 2011 1:12 PM writes...

But is such behavior that different from pushing atypical anti-psychotics to hyperactive kids and old people in nursing homes? If anything, they might end up killing or harming far fewer people.

Permalink to Comment

3. startup on August 4, 2011 1:43 PM writes...

Is it any good?

Permalink to Comment

4. newnickanme on August 4, 2011 1:44 PM writes...

When I read about the M&As, layoffs, promotion of off-label use, desperate attempts at patent extension and other rigamarole, I get awful heartburn AND a huge headache. BUT, I took two Axanum and felt great! You will, too!

Permalink to Comment

5. MoMo on August 4, 2011 1:52 PM writes...

I heard AZ is making a move on the makers of "Lazy Cakes"- the new brownies that contain melatonin and available now in New England. That will help their shore up their profits immensely!

Keep up that Innovative Thinking!

Permalink to Comment

6. partial agonist on August 4, 2011 3:16 PM writes...

Aspirin does so much stuff, everybody ought to be looking for a line extension by bundling with aspirin.

Trouble it, it needs to raise the cost by about a penny.

Having one pill instead of two would improve patient compliance, which must be their argument, but I don't see a great opportunity there.

Permalink to Comment

7. Anonymous on August 4, 2011 3:34 PM writes...

It'll be popular amongst AZ execs come stockholder meeting time...

Permalink to Comment

8. SteveM on August 4, 2011 5:08 PM writes...

Meh, Lovaza is just hyper-expensive fish oil yet docs write scripts for it.

AZ probably figures that as long as they can fool some of the docs some of the time, they'll make some money.

So what the heck...?

Permalink to Comment

9. Jose on August 4, 2011 7:51 PM writes...

Not sure I understand- is it just an absurd ploy to extend the patent?

Permalink to Comment

10. kenzhang on August 4, 2011 9:12 PM writes...

Nature review reports that patients with a history of cardiovascular or cerebrovascular disease, discontinuation of low-dose acetylsalicylic acid (ASA) therapy leads to a marked rise in the risk of future stroke or transient ischemic attack (TIA). Maybe Ananum can do something.

Permalink to Comment

11. NoDrugsNoJobs on August 4, 2011 9:23 PM writes...

Not sure why that when a drug company tries to make their drug more convenient or more tolerable or easier to administer they should be condemned and their motives impugned. If the combination makes sense, who should do the logical thing and combine them? Somebody else? Nobody?

Permalink to Comment

12. Anonymous on August 4, 2011 10:15 PM writes...

Here's an idea...combine Nexium with a SIRT1 activator from Sirtris. Polish it and sell it back to big pharma. Miracle medicine: you'll live forever and have a happy stomach!!!

Permalink to Comment

13. Morten G on August 5, 2011 2:41 AM writes...

Well I've had two different doctors prescribe me Avamys and the only difference over the generic is the counter ion. And the fact that it costs twice as much (which is cleverly disguised by halving the dosage and having people use twice as much).
So I don't see why this wouldn't work. Doctors don't care what the active ingredient is.

Permalink to Comment

14. Derek Lowe on August 5, 2011 10:28 AM writes...

NoDrugsNoJobs, to me the problem is that the improvement in convenience is minimal compared to the cost. And having such things emerge only when the patent is running out on the original drug does not add to the good feelings.

Permalink to Comment

15. NoDrugsNoJobs on August 5, 2011 11:50 AM writes...

Derek - if the improvement is not worth it then I reckon folks shouldn't buy it. What you are suggesting is that the combination doesn't make sense to sell since it as a combination at a higher price - so be it. However, if it increases the efficacy because folks don't take these two together normally or they don't do so reliably then maybe it is a worthwhile idea. I'm not sure who should say what makes sense? These days, the payors enforce a pretty strict discipline so they will have a tough audience for sure, not to mention the fda, EMEA, etc - I still don't get why the innovative free market that gives us better things at better prices across the spectrum suddenly is deemed insufficient to deal with drugs. For drugs, we are supposed to rely on a more reliable source for innovation, pricing, etc then the free market, the problem is, I am not sure what that is.

Permalink to Comment

16. Just Facts on August 5, 2011 7:28 PM writes...

Frankly, I don't see any problem with Axanum. Bravo AZ, I'd say. And hope that Anaxum will fetch some badly needed revenue to support more innovative R&D, and keep some of you employed...

Bashing Big Pharma may seem cool these days, but let's be reasonable, and perhaps a bit practical.

Permalink to Comment

17. Just Facts on August 5, 2011 7:53 PM writes...

Frankly, I don't see any problem with Axanum. Bravo AZ, I'd say. Hopefully, Anaxum will fetch some badly needed revenue to support more innovative R&D, and keep more medicinal chemists employed. And no, I don't work for AZ or any Pharama Co. for that matter.

Bashing Big Pharma may seem cool these days, but let's be reasonable, and perhaps a bit practical.

Permalink to Comment

18. Brian on August 5, 2011 8:40 PM writes...

Is that very much different than Vimovo? My wife's doctor prescribed that for her osteoarthritis and we then discovered that not only is it very expensive, but not covered by her prescription plan since both items are OTC separately.

Permalink to Comment

19. Terry on August 6, 2011 3:20 PM writes...

It is better than to develop a generic drug after the patents expiration.
Indeed similar combination of know drugs is very popular now due the hardness to find new chemical entry.

Permalink to Comment

20. sepisp on August 8, 2011 1:50 AM writes...

Sounds like a capitalist's miracle pill: first causes and then cures stomach ulcers.

Seriously, what happened to coadministration? Do you have to put all drug combinations like this through the full approval process - is it illegal to sell combined pills with two well-characterized APIs?

Permalink to Comment

21. RM on August 8, 2011 9:46 AM writes...

I find this especially amusing as Nexium is usually the drug trotted out as an example of a "me too" drug whose main function is to extend the patent life of a compound which was going generic. My understanding is that the improvement with Nexium compared to Prilosec is marginal at best, and not worth the cost difference for 90+% of the people taking it.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
How Not to Do It: NMR Magnets
Allergan Escapes Valeant
Vytorin Actually Works
Fatalities at DuPont
The New York TImes on Drug Discovery
How Are Things at Princeton?
Phage-Derived Catalysts
Our Most Snorted-At Papers This Month. . .